1. Targeted Care for COPD

2. Introduction

3. GOLD Recommendations: Initial Pharmacologic Treatment

4. GOLD Recommendations: Management Cycle

5. GOLD Recommendations: Follow-up Pharmacological Treatment

6. Pros

7. Percent Annual Rate Reduction of Moderate/Severe Exacerbations of COPD

8. Blood Eosinophil Counts, Exacerbations, and Response to the Addition of Inhaled Fluticasone to Vilanterol in COPD

9. Blood Eosinophils: Response to Beclomethasone/Formoterol in COPD Exacerbation Rate (FORWARD study)

10. Modeling Blood EOS to Identify Response to Budesonide in COPD – Post-Hoc Analysis

11. IMPACT Study: Blood Eosinophil Counts and Treatment Response

12. Predictors of Exacerbation Risk and Response to Budesonide: Post-hoc Analysis of 3 Randomized Trials

13. Cons

14. IMPACT Study: Blood Eosinophil Counts and Treatment Response

15. Pneumonia Risk in COPD Patients Receiving ICS Alone or in Combination (TORCH Study)

16. Relative Effect of ICS-Containing Medications on ECOPD vs Pneumonia

17. Blood Eosinophil Count and Pneumonia Risk in COPD: A Patient-Level Meta-Analysis

18. The Risk of Mycobacterial Infections Associated With ICS Use

19. ICS and the Risks of Diabetes Onset and Progression

20. Withdrawal of Inhaled Glucorticoids and Exacerbations of COPD

21. Eosinophilia, Frequent Exacerbations, and Steroid Response in COPD

22. Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD: SUNSET Trial

23. ICS in COPD: Friend or Foe?

24. ICS in COPD

25. Abbreviations

26. Abbreviations (cont)